For most heart failure medications, stopping leads to measurable clinical deterioration within a few weeks. The heart does not simply return to a neutral baseline; it loses the chemical support keeping it compensated, and in many cases the body overshoots in the wrong direction. A large review of drug withdrawal studies found this pattern held across nearly every medication class evaluated for heart failure with reduced pumping function. The specifics vary by drug, but the trajectory is consistent enough that researchers now argue the emphasis on getting patients onto the right medications needs to be matched by an equal emphasis on keeping them there without gaps.
How Quickly Deterioration Sets In
One of the clearest findings across withdrawal studies is the speed of decline. A 2024 review in the Journal of the American College of Cardiology examined what happens when long-term heart failure drugs are pulled and concluded that “meaningful clinical deterioration” appears within a few weeks for most of the medications studied. The review also identified four distinct patterns of what happens after a drug is stopped, ranging from a simple loss of the benefit the drug was providing to a dangerous rebound where the body’s response actually worsens beyond where it started.
That rebound pattern is especially concerning. When you take certain heart failure drugs for months or years, your body adapts to their presence. Removing the drug does not just erase the benefit; it can unmask a compensatory response that now swings too far in the opposite direction. Beta-blockers are the textbook example, discussed in more detail below, but the principle applies more broadly. The review’s authors stressed that even short-term gaps in treatment should be avoided and that clinicians need protocols to prevent unintentional interruptions.
The Numbers on Mortality and Hospitalization
The clinical consequences are not subtle. In a community-based heart failure population, patients who took less than 80% of their prescribed medications had roughly double the combined risk of death and cardiovascular hospitalization compared to adherent patients. That association held regardless of whether the medication was an ACE inhibitor, a beta-blocker, or a diuretic, and it persisted when the adherence threshold was shifted up or down.
A large UK general-practice study found that non-adherent heart failure patients had about a 31% higher risk of dying from any cause after adjusting for other health differences. Every 10% drop in the proportion of days a patient actually took their medications was linked to a 6% increase in death risk. Non-adherence was also tied to a higher rate of emergency hospital admissions.
Data from a Yemeni tertiary hospital painted an even starker picture in a population with high rates of non-adherence: patients who did not take their medications as prescribed were readmitted at roughly six times the rate of adherent patients, and their mortality rate was about four times higher.
What Happens With Specific Drug Classes
Heart failure treatment typically involves several medications working together, and each class carries its own withdrawal profile. Understanding these individually helps explain why the combined effect of stopping everything can be so severe.
Beta-Blockers
Abruptly stopping a beta-blocker is one of the most dangerous withdrawal scenarios in cardiology. During long-term use, the heart’s beta-adrenergic receptors upregulate, essentially becoming more numerous and more sensitive because the drug has been blocking them. When the drug is suddenly removed, all those extra receptors are exposed to the body’s normal adrenaline levels at once, producing a surge in heart rate, blood pressure, and cardiac workload that can trigger a heart attack or dangerous arrhythmia. This rebound phenomenon is well documented in both heart failure and stable heart disease patients, and guidelines universally warn against abrupt discontinuation.
ACE Inhibitors, ARBs, and Sacubitril-Valsartan
The renin-angiotensin system inhibitors form the backbone of heart failure therapy. A systematic review found that withdrawal studies for these drugs, while small, “show relatively convincingly that such withdrawals have untoward effects on cardiac structure, symptoms, and major outcomes.” The review’s authors concluded that current evidence discourages any attempt to discontinue these drugs in stable heart failure patients regardless of whether their heart function or symptoms have improved.
Sacubitril-valsartan, the newer combination drug, carries its own specific risk. A study of patients who switched from sacubitril-valsartan back to a standard ACE inhibitor or ARB found that their heart’s pumping ability declined and their functional class worsened, even though they remained on the older medications at appropriate doses. In other words, the conventional therapy could not fully replace what sacubitril-valsartan had been doing.
Diuretics
Diuretics manage the fluid overload that causes the swelling, breathlessness, and weight gain of heart failure. Withdrawal trials have consistently shown that patients need these drugs on an ongoing basis. In older adults specifically, patients were 25% more likely to restart a diuretic after it was discontinued compared to those who simply continued it, reflecting the rapid return of fluid-related symptoms. Diuretics remain a core part of managing congestion in all forms of heart failure.
Spironolactone (Mineralocorticoid Receptor Antagonists)
A study of patients with dilated cardiomyopathy whose heart function had improved looked at what happened when spironolactone was stopped. The results were striking: about 58% of patients in the withdrawal group relapsed, compared to just 13% in the group that kept taking it. That translates to more than a fourfold increase in the risk of relapse. The structural improvements that had been achieved while on the drug stopped progressing and began to reverse, while patients who continued spironolactone maintained their gains.
Digoxin
Digoxin withdrawal has been studied more extensively than most other heart failure drugs. In a landmark trial, patients switched from digoxin to placebo were nearly six times more likely to develop worsening heart failure than those who continued the drug. The placebo group showed deterioration across the board: worse exercise capacity, lower quality-of-life scores, decreased heart pumping function, increased heart rate, and weight gain from fluid retention. A meta-analysis pooling seven digoxin withdrawal studies found a 30% increase in heart failure hospitalizations, though no impact on overall mortality. In older patients, digoxin discontinuation was associated with a 5.5-fold risk of hospitalization compared to continuation.
SGLT2 Inhibitors
SGLT2 inhibitors are among the newest additions to heart failure treatment. A real-world study tracking patients who stopped these drugs found they had about 2.6 times the rate of heart failure hospitalization compared to those who continued. Common reasons for stopping included general weakness, excessive fluid loss, worsening kidney function, and urinary tract infections. The 2024 JACC review noted that SGLT2 inhibitors appear to follow a pattern where the benefit persists while on treatment and clinical worsening follows discontinuation.
The “My Heart Got Better” Trap
Perhaps the most counterintuitive finding in this entire area involves patients whose hearts have genuinely recovered. It seems logical that if your heart function returns to normal, you should be able to stop the medications that got you there. The TRED-HF trial directly tested this idea, and the results were sobering.
The trial enrolled patients with dilated cardiomyopathy whose hearts had recovered to normal pumping function. Half were randomly assigned to a carefully supervised, stepwise medication withdrawal over 16 weeks, while the other half continued their drugs. Within six months, 44% of patients in the withdrawal group relapsed, compared to none in the continuation group. When the continuation group later attempted their own supervised withdrawal, about 36% of them also relapsed. Overall, 40% of the 50 patients who attempted withdrawal relapsed during the study period. Most telling: among those who relapsed, 26 out of 50 did so within eight weeks of taking their last pill.
The withdrawal in TRED-HF was not careless. It followed a structured protocol: medications were tapered in a specific order, starting with the loop diuretic, then the mineralocorticoid receptor antagonist, then the beta-blocker, and finally the ACE inhibitor or ARB. Patients were reviewed every two weeks, with blood tests and clinical assessments at least monthly. Doses were cut in half at each step before being eliminated. Despite all these precautions, two in five patients still relapsed.
The implication is uncomfortable but clear: a recovered heart is not the same as a heart that never needed help. The medications are not just treating symptoms; they are structurally propping up a heart that, in many cases, will deteriorate without them. The idea that heart failure drugs are temporary fixes you can eventually graduate from does not hold up for a large proportion of patients.
Why People Stop Their Medications
Given the stakes, it is worth understanding what drives non-adherence. The reasons are often more practical than medical.
Cost is a major factor. In a community study of heart failure patients, those with poor medication adherence were dramatically more likely to report cost-related problems. Among patients poorly adherent to statin therapy, 46% said they had stopped a prescription because of cost, compared to just 6% of well-adherent patients. Similarly, 46% of poorly adherent patients said they had not filled a new prescription due to cost, versus 6% of adherent ones. Some reported skipping doses specifically to stretch their supply.
Side effects also play a significant role. SGLT2 inhibitors, for instance, cause urinary tract infections and excessive fluid loss in some patients, leading them to stop. Beta-blockers can cause fatigue and dizziness. Diuretics mean frequent trips to the bathroom. For a patient already dealing with the exhaustion and limitations of heart failure, adding medication side effects can feel like too much.
Cognitive impairment adds another layer. Heart failure is associated with reduced blood flow to the brain, and depression frequently co-occurs with the condition. Both impair the memory and executive function needed to manage a complex medication regimen. Patients with heart failure and co-existing depression or cognitive decline may genuinely struggle to understand or follow their treatment plans, not out of choice but out of diminished capacity.
And then there is the paradox of success: patients who feel better assume they no longer need the drugs. This is the same psychology behind the TRED-HF findings. When medications work well enough that symptoms disappear, the motivation to keep taking them evaporates. The absence of symptoms feels like proof of cure rather than proof that the medications are doing their job.
Older Adults and the Question of Deprescribing
The situation gets genuinely complicated in patients over 75, where the standard “never stop” advice collides with the realities of polypharmacy, frailty, and limited life expectancy. A systematic review examining down-titration and discontinuation in older heart failure patients found that the evidence is thin and the risks are real but context-dependent.
Down-titrating a renin-angiotensin system inhibitor was feasible in older patients with chronic kidney disease, with no detected difference in mortality. Beta-blocker discontinuation appeared manageable in patients with preserved (not reduced) heart pumping function. But diuretic and digoxin withdrawal remained problematic even in this population: patients were likely to need diuretics restarted, and digoxin discontinuation carried a 5.5-fold hospitalization risk. The review’s most honest conclusion was that the appropriateness of stopping or reducing heart failure drugs in people 75 and older remains “uncertain,” and the question of how frailty status should influence these decisions has barely been studied.
This uncertainty matters because older adults are the ones most likely to be on too many medications, most susceptible to side effects, and most in need of a thoughtful approach. A drug that prevents hospitalization in a 60-year-old with decades of life ahead may not serve the same purpose in a 90-year-old with advanced frailty and different priorities. But the data to guide those decisions simply does not exist yet in a rigorous form.
When Medications Are Intentionally Stopped
There are legitimate clinical scenarios where heart failure medications are deliberately paused or discontinued, and these are handled very differently from accidental non-adherence.
Before Surgery
Consensus recommendations call for holding ACE inhibitors, ARBs, and sacubitril-valsartan on the morning of surgery to avoid dangerous blood pressure drops under anesthesia. SGLT2 inhibitors require a longer pause: dapagliflozin, empagliflozin, and canagliflozin should be stopped three days before a procedure, and ertugliflozin four days before, to reduce the risk of a metabolic complication called euglycemic ketoacidosis. These are short, planned holds with specific restart timelines, which is very different from open-ended discontinuation.
End-of-Life Care
In hospice and palliative care settings, the goals shift from prolonging life to maximizing comfort. There are no specific guidelines for cardiac medications in hospice care for heart failure patients, so clinicians take an individualized approach to maintaining, changing, or discontinuing drugs based on patient preferences. A retrospective analysis found that while most cardiac medications were stopped before patients entered a palliative care unit, discontinuation was associated with higher pain scores and greater opioid requirements, particularly in heart failure patients. This finding complicates the assumption that stopping medications at end of life is straightforwardly beneficial and suggests that some heart failure drugs may contribute to comfort in ways that are not immediately obvious.
Herbal Supplements Are Not a Substitute
Some patients who stop or reduce their heart failure medications turn to complementary and alternative medicines, believing herbal remedies or supplements can fill the gap. The American Heart Association addressed this directly in a scientific statement, noting that while these products are widely used, clinical evidence supporting their use in heart failure “remains limited and controversial.” The products are largely unregulated, their interactions with remaining medications are poorly understood, and healthcare providers rarely ask about their use. Patients who replace evidence-based medications with unproven alternatives are essentially running the same withdrawal experiment described throughout this article, but without the monitoring that research protocols provide.
How Medications Are Restarted After a Gap
If you have missed doses or stopped your medications for any period, restarting is not as simple as picking up where you left off. The TRED-HF trial offers a useful template for how clinicians approach this. When patients in that study relapsed after withdrawal, their medications were restarted under close supervision with regular blood work and clinical assessments. The protocol that had been used to taper drugs off, going class by class in a specific order with dose adjustments every two weeks, essentially serves as a model for reintroduction as well, just in reverse.
In practice, restarting heart failure medications typically means beginning at lower doses and titrating back up, especially for beta-blockers and ACE inhibitors, which can cause blood pressure drops or slow heart rates if reintroduced at full dose. This takes time and medical oversight. It is one more reason prevention of gaps matters: getting back on track costs weeks of careful dose adjustment and clinic visits that would not have been necessary if the medications had simply been continued.
For patients who have stopped due to cost, side effects, or confusion about whether they still need treatment, the most productive step is an honest conversation with their prescriber. In many cases, alternatives within the same drug class may be cheaper or better tolerated. And for those who stopped because they felt well, the TRED-HF data makes the case that feeling well is the medication working, not a sign that you no longer need it.